Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has shown the ability in preclinical studies to cross the blood-brain barrier.
Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has shown the ability in preclinical studies to cross the blood-brain barrier.